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Abstract
Background: Multiple sclerosis (MS), an inflammatory disease of the central nervous system (CNS), is characterized
by blood-brain barrier (BBB) disruption and massive infiltration of activated immune cells. Engagement of
programmed cell death-1 (PD-1) expressed on activated T cells with its ligands (PD-L1 and PD-L2) suppresses T cell
responses. We recently demonstrated in MS lesions elevated PD-L1 expression by glial cells and absence of PD-1
on many infiltrating CD8 T cells. We have now investigated whether human brain endothelial cells (HBECs), which
maintain the BBB, can express PD-L1 or PD-L2 and thereby modulate T cells.
Methods: We used primary cultures of HBECs isolated from non-tumoral CNS tissue either under basal or inflamed
conditions. We assessed the expression of PD-L1 and PD-L2 using qPCR and flow cytometry. Human CD8 T cells
were isolated from peripheral blood of healthy donors and co-cultured with HBECs. Following co-culture with
HBECs, proliferation and cytokine production by human CD8 T cells were measured by flow cytometry whereas
transmigration was determined using a well established in vitro model of the BBB. The functional impact of PD-L1
and PD-L2 provided by HBECs was determined using blocking antibodies. We performed immunohistochemistry
for the detection of PD-L1 or PD-L2 concurrently with caveolin-1 (a cell specific marker for endothelial cells) on
post-mortem human brain tissues obtained from MS patients and normal controls.
Results: Under basal culture conditions, PD-L2 is expressed on HBECs, whilst PD-L1 is not detected. Both ligands
are up-regulated under inflammatory conditions. Blocking PD-L1 and PD-L2 leads to increased transmigration and
enhanced responses by human CD8 T cells in co-culture assays. Similarly, PD-L1 and PD-L2 blockade significantly
increases CD4 T cell transmigration. Brain endothelium in normal tissues and MS lesions does not express
detectable PD-L1; in contrast, all blood vessels in normal brain tissues are PD-L2-positive, while only about 50%
express PD-L2 in MS lesions.
Conclusions: Our observations suggest that brain endothelial cells contribute to control T cell transmigration into
the CNS and immune responses via PD-L2 expression. However, such impact is impaired in MS lesions due to
downregulation of endothelium PD-L2 levels.
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Background
Multiple sclerosis (MS) is an inflammatory disorder of
the central nervous system (CNS), pathologically charac-
terized by focal demyelination, neuronal damage, glial
cell activation and massive infiltration of immune cells
[1]. Under physiological conditions, the blood-brain bar-
rier (BBB) restricts and regulates the entrance of pro-
teins, nutrients and cells from the periphery to the CNS
[2,3]. However, during MS pathogenesis, the BBB
impairment facilitates the infiltration of peripheral
immune cells into the CNS [1]. Infiltrating cells detected
within MS lesions include macrophages and T cells.
Although CD4 T cells have been established as impor-
tant players in MS pathogenesis, CD8 T cells are
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increasingly recognized as potential contributors to tis-
sue damage [4,5]. CD8 T lymphocytes are detected in
MS lesions, preferentially in the parenchyma and in
greater numbers than their CD4 counterparts [6-11].
Programmed cell death-1 (PD-1), a member of the B7-
CD28 family, is a co-inhibitory receptor expressed by a
variety of activated immune cells, including T cells [12].
The interaction between PD-1 and its ligands (PD-L1 or
PD-L2) suppresses T cell responses including prolifera-
tion, cytokine production, and cytotoxicity [12-15]. PD-
L1 is expressed by activated immune cells [16] such as
T cells, B cells, macrophages, dendritic cells and micro-
glia [17], as well as by non-immune cells such as
endothelial and epithelial cells [18,19], and astrocytes
[17]. PD-L2 expression is more restricted and has been
observed on macrophages, dendritic cells, mast cells
[16], and endothelial cells from various organs
[15,20-23]. Several groups have established that PD-L1
and PD-L2 expression varies between different endothe-
lial sources and species (mouse vs. human) and that
such expression displays immuno-regulatory functions
[15,20,21,23]. However, whether human brain endothe-
lial cells (HBECs) via the expression of PD-L1 and/or
PD-L2 impact on immune responses has not been
investigated.
Studies performed in the experimental autoimmune
encephalomyelitis (EAE) mouse model of MS have
underlined the contribution of PD-1 and its ligands to
dampening disease susceptibility or severity [24-26].
Moreover, blocking PD-1 using antibodies or knock-out
mice led to an elevated number of CNS infiltrating
immune cells, especially CD8 T cells [25-27]. We have
previously shown [17] that although PD-L1 is barely
detectable in the brain of normal controls, its expression
is significantly increased in MS lesions, especially on
astrocytes and microglia/macrophages [17]. We
observed that although the very few CD8 T cells found
in control brain are all PD-1 positive, the majority of
infiltrating CD8 T cells in MS lesions do not express
PD-1. Whether T cell infiltration into the inflamed CNS
of MS patients is modulated by the BBB via the expres-
sion of PD-L1 and/or PD-L2 is still unresolved.
In this study, we investigated PD-L1 and PD-L2
expression by primary cultures of HBECs and the
impact of such expression on CD8 T cell functions. We
demonstrate that HBECs express low/undetectable levels
of PD-L1 at basal level in vitro, but most of them
express PD-L2 and both ligands are up-regulated in
response to pro-inflammatory stimuli. Moreover, we
establish that via the expression of PD-L1 and PD-L2,
HBECs can locally modulate human T cell responses,
leading to decreased migration of CD8 and CD4 T cells
through an in vitro BBB model. Finally, we assessed the
expression of PD-L1 and PD-L2 in post-mortem human
brain tissues. Whereas PD-L1 is not detectable on
endothelial cells in control or MS tissue sections, PD-L2
is robustly detected in control brain tissues but its
expression is partially lost in MS lesions.
Methods
Isolation and culture of human brain endothelial cells
CNS tissue was obtained from surgical resections per-
formed for the treatment of non-tumor related intract-
able epilepsy as previously described [28]. Consent and
ethical approval were given prior to surgery (BH
07.001). Human brain endothelial cells (HBECs) were
grown in M199 medium (Invitrogen, Burlington, ON,
Canada) supplemented with 10% fetal bovine serum,
20% normal human serum, endothelial cell growth sup-
plement (5 μg/ml) and insulin-selenium-transferin pre-
mix on 0.5% gelatin-coated tissue culture plates (all
reagents from Sigma, Oakville, ON, Canada).
Isolation of human T cells
A written informed consent was obtained from healthy
donors in accordance with the local ethical committee
(HD 07.002 and BH 07.001). Peripheral blood mononuc-
lear cells (PBMCs) were obtained by Ficoll density gradi-
ent as previously described [29]. CD8 or CD4 T cells
were positively isolated from PBMCs using either CD8
or CD4 beads respectively (MACS, Miltenyi Biotec,
Auburn, CA, USA) according to the manufacturer’s
instructions; purity assessed by flow cytometry was typi-
cally > 95%.
RNA isolation, reverse transcription, and qPCR
Total RNA was extracted and transcribed into cDNA as
previously described [17,30]. Relative mRNA expression
was determined by quantitative real-time PCR (qPCR)
using primers and TaqMan FAM-labeled MGB probes
for PD-L1 and PD-L2 and ribosomal 18S (VIC-labeled
probe, used as an endogenous control) obtained from
Applied Biosystems (Foster City, CA, USA) according to
manufacturer’s instructions and as previously described
[17,30].
Flow cytometry
Cells were stained for surface and/or intracellular mole-
cules as previously described [17,31], acquired on a
LSRII (BD Biosciences, Mississauga, ON, Canada) and
analyzed with FlowJo software (Treestar, Ashland, OR,
USA). Mouse monoclonal antibodies directed at human
protein and conjugated to biotin, fluoroscein isothiocya-
nate (FITC), Alexa Fluor® 700, phycoerythrin, Pacific
Blue, or allophycocyanin were used. Surface stainings
targeted: PD-L1 (eBioscience, San Diego, CA, USA), PD-
L2 (eBioscience), HLA-ABC (Biolegend, San Diego, CA,
USA), CD4 and CD8 (BD Biosciences). Intracellular
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stainings targeted: granzyme B (Caltag, Buckingham,
UK) and IFN-g (BD Biosciences). Appropriate isotype
controls were used for all stainings. Δmedian fluores-
cence intensity (ΔMFI) was calculated by subtracting the
fluorescence of the isotype from that of the stain.
Migration assay
Migration assays were performed in a modified Boyden
chamber as previously described [28]. HBECs plated on
Boyden chambers (Collaborative Biomedical Products,
Bedford, MA) were stimulated with IFN-g (200 U/ml)
and TNF (200 U/ml) for 24 hours and then treated
either with isotype control antibodies or blocking anti-
bodies specific for PD-L1 (10 μg/ml, eBioscience) and/or
PD-L2 (10 μg/ml, eBioscience) for one hour at 37°C.
CD8 or CD4 T cells that had been exposed to plate-
bound anti-CD3 (0.9 μg/ml, clone OKT3, purified in
house) and anti-CD28 antibodies (1 μg/ml, BD Bios-
ciences) for 72 hours were then added to the upper
chamber (1 × 106 cells per Boyden chamber) and
allowed to migrate for 24 hours across HBECs. FITC-
labeled BSA (50 μg/ml; Invitrogen) was concurrently
added to the upper chamber and 50 μl samples were
harvested from the upper and lower chambers at differ-
ent time points and the fluorescence intensity in these
samples was measured using a Synergy4 Biotek micro-
plate reader. The diffusion rate of the FITC-BSA, a mea-
sure of the permeability, was expressed as a percentage
and calculated as followed: [(BSA lower chamber)/(BSA
upper chamber)] × 100. After migration, cells from the
lower and upper chambers were collected, counted, and
stained for different markers.
Co-culture assay
HBECs were plated (5 × 105 cells per well in a 24-well
plate), and after 3 days when reaching confluence, sti-
mulated with IFN-g (200 U/ml) and TNF (200 U/ml)
for 24 hours. HBECs were washed three times to
remove these inflammatory cytokines. An isotype con-
trol antibody or blocking antibodies specific for PD-L1
(10 μg/ml) and/or PD-L2 (10 μg/ml) were added one
hour at 37°C to allow them to bind to their cognate
ligands. Isolated alloreactive human CD8 T cells were
labeled with CFSE as previously described [29] and
then subsequently added (2 × 105 cells per well) to
HBECs without removing the blocking antibodies and
in the presence of anti-CD3 (0.18 μg/ml) and anti-
CD28 (1 μg/ml) antibodies. Blocking antibodies and
anti-CD3 and anti-CD28 were left in the wells for the
entire co-culture. After a 6 day co-culture, CD8 T cells
were collected and stained for Live/dead fixable Aqua
dead cell stain kit (Invitrogen) to exclude dead cells
and stained for CD8, granzyme B, and IFN-g for flow
cytometry assessment.
Immunohistochemistry
Post-mortem brain sections from tissue donors without
CNS disease and patients diagnosed clinically and con-
firmed by neuropathological examination as having MS
were obtained from the NeuroResource tissue bank,
UCL Institute of Neurology, London, U.K. Tissues were
donated to the tissue bank with informed consent fol-
lowing ethical review by the London Research Ethics
Committee, UK. This study was approved by the
CHUM Ethical Committee (HD 07.002). Snap-frozen
coded sections (~1 cm2 and 10 μm thick) were cut from
blocks of normal control and MS brain tissues. Sections
cut before and immediately after the ones used for the
immunofluorescence studies were stained with oil red O
and hematoxylin, and scored as previously described
[32] (Table 1). Sections were air-dried, fixed in cold
acetone for 10 min, and blocked for non-specific bind-
ing for 1 hour with 10% donkey (for PD-L2 detection)
or goat serum (for PD-L1 detection). Primary antibodies
targeting PD-L1 (25 μg/ml, Biolegend) or PD-L2 (2 μg/
ml, RD Systems, Burlington, ON, Canada) was incubated
1 hour at room temperature and then overnight at 4°C.
Sections were then washed with PBS and incubated for
40 minutes with appropriate secondary antibodies: Alexa
Fluor® 488-conjugated goat-anti-mouse for PD-L1 and
Alexa Fluor® 488-conjugated donkey-anti-goat for PD-
L2. Sections were then incubated at room temperature
for 1 hour with antibodies targeting cell specific markers
for endothelial cells (rabbit-anti-human-caveolin-1,
Santa Cruz Biotechnology, Santa Cruz, CA, USA) fol-
lowed by 40 minutes with secondary antibody (Rhoda-
mine-conjugated goat-anti-rabbit, Jackson
Immunoresearch, West Grove, PA, USA). Finally, sec-
tions were incubated with a nuclear stain TO-PRO®-3
iodide (Invitrogen), treated with Sudan Black and
mounted as previously described [17]. Controls were
concurrently carried out on adjacent sections using
appropriate primary isotype controls at the same con-
centrations. Slides were observed using a SP5 Leica con-
focal microscope. Confocal images were acquired
simultaneously in different channels throughout 4-8 μm
z-stack every 0.2-0.5 μm. We validated staining specifi-
city by lack of signal only when the corresponding laser
was turned off but not when others were still on. Several
fields (> 5) containing blood vessels were taken ran-
domly on each section and used for quantification of
positive cells. Moreover, we confirmed the absence of
bleed-through by re-examining selected sections using
sequential scanning.
Statistical analyses
Statistical analyses were performed using PRISM Graph-
pad™ software (La Jolla, CA, USA) and included Stu-
dent’s t-test; P-values < 0.05 were considered significant.
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Results
Pro-inflammatory cytokines increase PD-L1 and PD-L2
expression by human brain endothelial cells
We evaluated whether HBECs express detectable levels of
PD-L1 and/or PD-L2. Primary cultures of HBECs were
either left untreated or activated with pro-inflammatory
cytokines IFN-g, TNF, or IFN-g+TNF to mimic the pro-
inflammatory environment typically observed in the CNS
of MS patients. HBECs expressed very low PD-L1 but
detectable PD-L2 mRNA levels under basal conditions as
assessed by qPCR (Figure 1A). IFN-g+TNF treatment
robustly increased those levels (Figure 1A), almost reach-
ing statistical significance for PD-L1 expression (n = 4
donors, untreated vs. IFN-g+TNF p = 0.075). Detection of
PD-L1 and PD-L2 proteins by flow cytometry allowed
quantification of both percentages of HBECs expressing
these molecules and intensity of such expression (ΔMFI);
typical flow cytometry detection is shown (Figure 1B).
HBECs under basal conditions expressed very low/unde-
tectable levels of PD-L1 protein (Figure 1B: 1.3%), while
PD-L2 protein was already expressed by the majority of
cells reaching 78.5% (Figure 1B). In response to different
cytokine treatments tested, the proportion of HBECs
expressing PD-L1 significantly increased reaching over
96%, especially in response to IFN-g and IFN-g+TNF
(Figure 1B) (mean n = 4, PD-L1+ cells: IFN-g: 98.5 ± 1.2%
and IFN-g+TNF 99.4 ± 0.3%; ** p < 0.003 compared to
untreated), while TNF (Figure 1B) had a more modest
impact (mean n = 4, PD-L1+ cells: 54.1 ± 15.6%, p = 0.065
compared to untreated). All cytokine treatments tested
also boosted the proportion of HBECs expressing PD-L2
reaching over 96% (mean n = 4, PD-L2+ cells: IFN-g: 97.2
± 1.4%; IFN-g+TNF: 98.9 ± 0.6%; TNF: 97.5 ± 2.4%).
Moreover, cytokine treatments led to not only increased
proportions of HBECs expressing PD-L1 or PD-L2 but
also elevated intensity as shown by ΔMFI; IFN-g+TNF
having the more potent impact for PD-L1 levels (Figure
1C). We also observed an upregulation of MHC-class I
molecules (HLA-ABC, Figure 1B) on HBECs upon cyto-
kine treatment. In agreement with our flow cytometry
results, PD-L1 was undetectable by immunocytochemistry
on untreated HBECs but reached detectable levels after
IFN-g+TNF treatment, while PD-L2 was detectable both
under basal conditions and following pro-inflammatory
treatments (data not shown).
Human brain endothelial cells partially block T cell migration
through an in vitro model of the BBB via PD-L1 and PD-L2
We elected to address whether the expression of PD-L1
and PD-L2 by HBECs influences their capacity to
Table 1 Description of post-mortem brain sections
Block M/
F
Age
(Y)
DD
(Y)
Cause of death DFT
(h)
Sample
Type
ORO,
hematoxylin
Score
Summary observations on ORO-stained sections
1 F 68 - Colo-rectal metastatic
tumour
23 NC W, OV,
R
0, 0 Normal white matter and cortical grey matter
2 M 49 - Myocardial infarction and
coronary artery thrombosis
11 NC W, PV, R 0, 0 Normal white matter and grey matter.
3 M 53 - Cardiac arrest 19 NC W, OSv,
R
0, 0 Normal white matter.
4 F 47 20 Bronchopneumonia 9 MS AQ, FSv,
L
4, 3 White matter and grey matter surrounding active plaque.
ORO+ cells in blood vessel walls and parenchyma.
5 F 47 20 Bronchopneumonia 9 MS AQ, PSv,
L
5, 4 Large plaque with active and some subacute and chronic
areas. Large perivascular cuffs. White and grey matter.
6 F 37 10 Bronchopneumonia 24 MS AQ,
basal
ganglia, L
3, 3 Large subacute plaque with perivascular cuffing; areas of
grey matter.
7 F 71 32 Bronchopneumonia 19 MS SAQ, O
pole Sv, L
2, 0 Hypocellular plaque surrounded by patchy abnormal-
appearing white matter.
8 F 29 8 Bronchopneumonia 11 MS SAQ,
cerebellum,
R
1, 1 Large subacute plaque with hypercellular areas.
9 F 60 34 Renal failure 24 MS SAQ, TV,
L
2, 4 Large subacute plaque with many large and small
perivascular cuffs.
10 F 49 11 Bronchopneumonia 16 MS CQ, F
pole V, R
0, 2 Large chronic plaque surrounded by pale abnormal white
matter.
Abbreviations:
DD: disease duration; DFT: time between death and sample freezing; NC: normal control; W: white matter; MS: multiple sclerosis; AQ: active plaque; SAQ:
subacute plaque; V: ventricular; Sv: subventricular; F: frontal; P: parietal; T: temporal; O: occipital; R: right; L: left.
ORO and cuffing: Scored on a scale of 0 to 5 for ORO and haematoxylin staining; 0 is what would be expected in normal control white matter. Data is averaged
from duplicate sections cut immediately before and after the serial sections cut.
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Figure 1 Pro-inflammatory stimulation increases PD-L1 and PD-L2 expression on human brain endothelial cells . Human brain
endothelial cells were either left untreated or stimulated with inflammatory cytokines as indicated and then PD-L1 and PD-L2 expression was
determined by qPCR and flow cytometry. A. Pooled data (n = 4) of PD-L1 and PD-L2 mRNA relative levels in response to IFN-g+TNF. B.
Representative flow cytometry dot plots illustrating PD-L1 and PD-L2 protein expression versus HLA-ABC expression in response to different
cytokines. C. PD-L1 (left panel) and PD-L2 (right panel) protein expression (ΔMFI) observed for 4 distinct donors. Student’s t-test: * P < 0.05, ** P
< 0.01.
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regulate the migration of CD8 and CD4 T cells into the
CNS. We used a well-established in vitro model of the
BBB in which HBECs are seeded in the upper compart-
ment of a Boyden chamber [33], inflamed, and then
incubated with either anti-PD-L1 and anti-PD-L2 block-
ing antibodies or isotype control antibodies. CD8 or
CD4 T cells that have been stimulated for 3 days with
anti-CD3+anti-CD28 to maximally increase the expres-
sion of PD-1 were added to the Boyden chamber. We
have previously shown that although on average only
14% of ex vivo CD8 T cells expressed PD-1, this propor-
tion reached 64% after such a stimulation [17]. We
observed significantly greater numbers of CD8 T cells
migrating through the in vitro BBB when blocking anti-
bodies targeting PD-L1+PD-L2 were added compared to
the isotype control (Figure 2A). Blocking only one
ligand PD-L1 or PD-L2 had a more modest impact on
the number of migrated CD8 T cells (data not shown).
In parallel, we performed a permeability assay using
BSA-FITC as a permeability tracer and observed an
identical diffusion of BSA-FITC for the isotype control
and the blocking antibodies conditions (Figure 2B).
These results demonstrate that the elevated CD8 T cells
transmigrating through the in vitro BBB in the presence
of anti-PD-L1+anti-PD-L2 blocking antibodies were not
due to a general disruption of the brain endothelial cell
monolayer. Similarly, blocking these ligands led to an
increased number of CD4 T cells migrating through our
in vitro BBB (Figure 2C-D). Therefore, PD-L1 and PD-
L2 expressed by HBECs contribute to dampening T cell
migration through the barrier created by these specia-
lized cells.
Human brain endothelial cells modulate T cell responses
via PD-L1 and PD-L2
Previous studies have shown the capacity of PD-L1 and
PD-L2 expressing endothelial cells, especially human
umbilical vein endothelial cells (HUVECs) and mouse
Figure 2 Blocking PD-L1/2 enhances migration of CD8 and CD4 T cells through an in vitro BBB model. HBECs were plated to the upper
chamber of a Boyden chamber and then inflamed. Activated CD8 (A, B) and CD4 (C, D) T cells were added to the upper chamber and allowed
to migrate for 24 hours in the presence of an isotype control antibody or blocking antibodies specific for PD-L1 and PD-L2. A-C. Graphs
representing the number of CD8 (A) or CD4 (C) T cells migrating through the in vitro BBB for 3-5 distinct T cell donors on 2-3 HBECs
preparations. Student’s t-test: ** P < 0.01. B-D. Graphs representing the percentage of BSA-FITC diffusion as a measure of permeability of the in
vitro BBB, showing one representative experiment out of three.
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cardiac endothelial cells, to inhibit T cell responses
[15,20-23]. However, whether human brain endothelial
cells could modulate CD8 T cells responses has not
been previously determined. Alloreactive human CD8 T
cells were labeled with CFSE and then added to
inflamed HBECs cultures that have been pre-incubated
with either isotype control antibodies or anti-PD-L1 and
anti-PD-L2 blocking antibodies. Proliferation (CFSE low
cells) and production of IFN-g and granzyme B were
analyzed by flow cytometry. As shown for 2 different
donors in Figure 3, blocking PD-L1 and PD-L2 had no
consistent effect on CD8 T cell proliferation (Figure 3A,
B). On the other hand, a modest but significant increase
in the percentage of IFN-g producing CD8 T cells (Fig-
ure 3A, C) was observed for all donors when PD-L1 and
PD-L2 were blocked compared to the isotype control.
The percentage of granzyme B producing CD8 T cells
(Figure 3A, D) was significantly elevated when both
ligands were blocked compared to the isotype control.
Blocking only PD-L1 or only PD-L2 led to a partial
increase of IFN-g and granzyme B production in com-
parison to the blockage of both proteins (data not
shown). Our results demonstrate that PD-L1 and PD-L2
expressed by HBECs were sufficient to significantly
diminish the effector functions (cytokines and lytic
enzyme) of human CD8 T cells.
Human brain endothelial cells in MS lesions do not
express PD-L1, while PD-L2 is down-regulated
To assess whether endothelial cells in the CNS of MS
patients express PD-L1 and/or PD-L2, we performed
immunohistochemistry on post-mortem brain tissues
obtained from normal controls and MS patients (see
description in Table 1). MS lesions were characterized
using oil red 0 (ORO) and hematoxylin scoring as being
acute, containing numerous phagocytic macrophages
that had recently engulfed lipid-containing debris, or
subacute, containing demyelinated areas but demon-
strating less recent myelin destruction. Brain sections
were stained for PD-L1 or PD-L2 and caveolin-1, a spe-
cific marker for endothelial cells, or appropriate isotype
controls. Six to ten fields (at 630×, each field covering
0.0625 mm2) per section containing caveolin-1+ blood
vessels were selected randomly (3 sections from controls
and 7 sections MS lesions) and thoroughly analyzed to
determine the percentage of blood vessels positive for PD-
L1 or PD-L2, and representative fields are illustrated (Fig-
ures 4, 5). As shown in our earlier study [17], no or very
low expression of PD-L1 was observed in the CNS of nor-
mal controls (Figure 4A-C). However, as we have pre-
viously reported, an elevated expression of PD-L1 was
observed on astrocytes and microglia/macrophages in MS
lesions, but no co-localization was found between PD-L1+
cells and caveolin-1+ cells (Figure 4E-G and 4I-K).
In contrast to PD-L1, PD-L2 was easily detected in
normal control brain sections, and was co-localized with
caveolin-1+ cells (Figure 5A-C, M). Whereas all caveo-
lin-1+ cells were positive for PD-L2 in normal control
sections, PD-L2 was only expressed by a subset of
endothelial cells in MS sections (Figure 5E-G, I-K, N).
Quantification of blood vessels identified by caveolin-1
labeling demonstrated that all blood vessels in normal
tissues expressed PD-L2 but only 50% expressed PD-L2
in MS lesions (Figure 5O). The reduced PD-L2 expres-
sion was observed on vessels of all diameters and
regardless whether these lesions were acute, sub-acute,
or chronic. However, diminished PD-L2 expression was
localized within areas of demyelination and not outside
MS lesions as assessed by Sudan black staining [17].
Figure 3 Expression of PD-L1 and PD-L2 on HBECs regulates
CD8 T cell responses. HBECs were first stimulated with IFN-g and
TNF for 24 hours. After three washes, HBECs were incubated either
with an isotype control antibody or blocking antibodies specific for
PD-L1 and PD-L2, prior to the addition of ex vivo human CD8 T cells
labeled with CFSE in the presence of anti-CD3 and anti-CD28. These
reagents were left for the entire co-culture period. After 6 days of
co-culture, proliferation, IFN-g and granzyme B were analyzed by
flow cytometry. A. Representative dot plots of CD8 T cell responses
for 2 different donors: proliferation assessed by CFSE dilution (X axis)
vs. IFN-g (top panel) or granzyme B (bottom panel) production (Y
axis). Flow cytometry plots are gated on living CD8 T cells. B-D.
Data obtained from 5 CD8 T cell donors on 3 HBECs preparations
for proliferation (B), IFN-g (C) and granzyme B production (D).
Student’s t-test: * P < 0.05, ** P < 0.01.
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PD-L2 labeling was either easily detectable or absent
(Figure 5). PD-L2+ but caveolin-negative cells with a
morphology suggestive of infiltrating leukocytes were
observed around some blood vessels in MS lesions,
whereas outside lesions and in normal control sections
these cells were not seen.
Discussion
In this study, we demonstrate that primary cultures of
HBECs express robust basal levels of PD-L2 and
increased levels of PD-L1 and PD-L2 in response to
pro-inflammatory cytokines. Such PD-1 ligand expres-
sion contributes to the capacity of HBECs to reduce the
migration and activation of human T cells. Our analysis
of post-mortem human brain tissues underlines that
PD-L2 is expressed by all brain endothelial cells under
normal physiological conditions but that a significant
proportion of these cells do not express PD-L2 in MS
brain lesions. Finally, PD-L1 although easily observed on
other CNS cell types in MS brain lesions is not detected
on brain endothelial cells.
PD-L1 and PD-L2 expression by endothelial cells from
various origins, but not CNS, has been previously shown.
Using primary cultures of HBECs, we observed that under
physiological conditions PD-L1 was not detected as
assessed by flow cytometry and qPCR. On the other hand,
PD-L2 was already highly expressed at basal level (Figure
1). Upon inflammation, both ligands were up-regulated,
reaching around 100% of cells positive for these ligands
(Figure 1). Previous studies have shown similar observa-
tions using human umbilical vein endothelial cells
(HUVECs) by qPCR and flow cytometry: HUVECs did not
express PD-L1 [15,22,23], but did bear considerable PD-
L2 levels under basal conditions [15]. Moreover, IFN-g sti-
mulation increased both PD-L1 and PD-L2 expression
while the combination IFN-g+TNF was even more potent
[15]. Also using flow cytometry, human cornea endothelial
cells increased PD-L1 and PD-L2 levels following IFN-g
Figure 4 PD-L1 is not detectable on brain endothelium of normal controls and MS patients. Micrographs showing brain sections stained
for PD-L1 (green), caveolin-1 (red) and nucleus (blue) of one representative normal control (A-C) and two representative MS donors (E-G, I-K). In
control subjects, PD-L1 immunoreactivity is not detectable (A). In contrast, PD-L1 is robustly expressed in MS lesions but it does not co-localize
with the endothelial cell marker (E-G, I-K). Corresponding isotypes are shown in D, H and L. Scale bar: 25 μm.
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Figure 5 PD-L2 is expressed on brain endothelial cells of normal controls, but down-regulated in MS lesions. Micrographs showing brain
sections stained for PD-L2 (green), caveolin-1 (red) and nucleus (blue) of one representative normal control (A-C, M) and two representative MS
donors (E-G, I-K, N). PD-L2 immunoreactivity is detected on all blood vessels visualized by caveolin-1 positive labeling in control subjects (C, M).
However, in MS lesions, while PD-L2 reactivity is detected on blood vessels (E-G, N), a subset of blood vessels visualized by caveolin-1 labeling
does not express detectable PD-L2 (I-K, N). Corresponding isotypes are shown in D, H and L. Scale bar: 25 μm (A-L), 400 μm (M, N). White arrows
indicate examples of caveolin-1+ PD-L2- blood vessels, whereas orange arrows indicate examples of caveolin-1+ PD-L2+. O. Quantification of the
percentage of blood vessels expressing PD-L2 in sections from normal controls (n = 3) and MS patients (n = 7). At least 6 blood vessels were
counted for each section. Student’s t-test: *** P < 0.001.
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stimulation [20]. In contrast, mouse heart endothelial cells
upregulated PD-L1 levels in inflammatory conditions but
did not express detectable levels of PD-L2 under basal or
activated conditions as assessed by flow cytometry and
microscopy [15,21], suggesting distinct regulation of PD-
L1 and PD-L2 by endothelial cells in different species and
in different organs.
Massive infiltration of immune cells into the CNS is
one of the first steps leading to the formation of new MS
lesions and mechanisms controlling such infiltration have
not been completely elucidated. Blocking PD-L1 and PD-
L2 in EAE, the mouse model of MS, leads to earlier onset
and increased severity of the disease, mainly due to ele-
vated number of infiltrating immune cells, especially
CD8 T cells [25,26]. In our study, we demonstrated that
blocking PD-L1 and PD-L2 on HBECs leads to elevated
number of CD8 and CD4 T cells migrating through an in
vitro BBB model (Figure 2), supporting a contributing
role for these ligands expressed by the local endothelium
in regulating immune cell infiltration into the CNS. In
contrast, our group has recently shown that MHC class I
blockade does not modify the migration of human CD8
T cells across BBB-endothelial cells [34]. These observa-
tions also demonstrate that although CD8 T cells and
HBECs were obtained from different human donors, the
allo-reactivity did not play a role in CD8 T cell migration
in our in vitro BBB model. Furthermore, it has been pre-
viously demonstrated that the ligation of PD-1 blocks the
b1 and b2 integrin-mediated adhesion by human T cells
induced with anti-CD3 [35]. Therefore, based on these
published data and our own novel data, we suggest that
the binding of PD-1 on T cells by PD-L1/2 on HBECs
prevents these T cells from crossing the endothelium
potentially via a mechanism implicating integrins. CD8 T
cells were shown to be particularly affected by a general
PD-L1 and PD-L2 blockade in the EAE model [26,27].
We can speculate that PD-1 ligand expression by the
CNS-endothelium may play a role in regulating the
migration of other activated immune cells expressing the
cognate receptor, as PD-1 is expressed not only on acti-
vated T cells but also on B cells and monocytes [36].
Endothelial cells from different organs have been
shown to display the capacity to modulate T cell
responses via the expression of PD-L1 and/or PD-L2
[15,21-23]. In our studies, blocking PD-L1 and PD-L2
on inflamed HBECs did not affect the proliferation of
CD8 T cells. However, it had an impact on the produc-
tion of IFN-g and granzyme B (Figure 3). Rodig and col-
leagues have similarly demonstrated that blocking PD-
L1 and/or PD-L2 on HUVECs increased the production
of IFN-g, but did not influence proliferation and IL-2
production by CD8 T cells [15]. This group also
reported that blocking PD-L1 on mouse heart endothe-
lial cells increase the killing capacity of CD8 T cells. We
believe that the effects seen in our in vitro assays were
mainly due to the blocking of PD-L1 and PD-L2 on
inflamed HBECs but we cannot rule out that the anti-
PD-L1 antibody could bind to PD-L1-expressing acti-
vated CD8 T cells. However, as we could not detect PD-
L1 on ex vivo CD8 T cells and only low levels of PD-L1
on a small fraction of CD8 T cells (8-20%) after anti-
CD3+anti-CD28 activation (data not shown), this would
be a less important contribution.
Distinct PD-L1 and PD-L2 expression has been
reported in different human organs. Several groups
demonstrated that PD-L1 and/or PD-L2 are detected in
immuno-privileged organs under physiological condi-
tions. PD-L1 is elevated in human placenta, while PD-
L2 is highly expressed on the endothelium of placenta
blood vessels [37]. Although PD-L1 is constitutively
expressed in testis, another immuno-privileged organ,
no PD-L2 is observed [38]. PD-L1 is also constitutively
expressed at high levels by corneal epithelial cells. How-
ever, these cells bear significantly reduced PD-L1 levels
during dry eye disease, a T-cell mediated inflammation
[39], paralleling our observations for PD-L2 on human
CNS endothelium in controls vs. MS. Using an endothe-
lial cell specific marker (caveolin-1), we easily detected
PD-L2 expression by all blood vessels (caveolin-1+) in
post-mortem CNS tissues obtained from normal con-
trols, but only on about 50% of blood vessels in MS
lesions (Figure 5). We observed non-endothelial cells
around blood vessels expressing PD-L2 in MS lesions.
According to the shape and the localization of these
cells, we hypothesize that these are infiltrating immune
cells. Experiments performed in EAE documented PD-
L1 and PD-L2 detection on a fraction of infiltrating
immune cells such as macrophages, dendritic cells and
microglia [26,40]. We could not detect PD-L1 on CNS
brain endothelium although this ligand was easily
observed on other CNS cells in MS lesions (Figure 4)
and has been observed on malignant gliomas [41]. We
have previously shown that PD-L1 is significantly ele-
vated in MS brain lesions especially on astrocytes and
microglia/macrophages [17], while this ligand is barely
detectable in normal controls. These observations corre-
late with our previous in vitro data obtained with pri-
mary cultures of glial cells; we detected low levels of
PD-L1 on microglia and astrocytes under basal condi-
tions but a significant increase of PD-L1 levels on these
cells upon pro-inflammatory stimulation [17]. In con-
trast to our observations in human CNS, PD-L2 was not
detected on CNS cells of control and EAE animals,
although PD-L1 was observed on resident brain cells,
including the endothelium, in EAE mice [26,42]. These
results support the notion that PD-L1 and PD-L2
expression is differently regulated in human and murine
CNS [42].
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Recent work suggests that the expression of PD-1
ligands is regulated by different promoters in distinct
cell types [43]. Indeed, whereas murine PD-L2 expres-
sion has been shown to be controlled by NF-B and
STAT6, PD-L1 expression is not [42]. Moreover, plati-
num-based chemotherapeutics have been shown to
downregulate PD-L2 expression in human dendritic and
tumor cells [44] via a STAT6-mediated mechanism.
Therefore, a more detailed dissection of the mechanisms
regulating PD-L1 and PD-L2 expression under physiolo-
gical and disease conditions is warranted and could
result in new therapeutic tools.
Our in vitro data showed that HBECs express low or
no PD-L1 but high PD-L2 levels under basal conditions;
similarly in normal control brain tissues we did not
detect PD-L1 but observed robust PD-L2 expression by
the brain endothelium. Although inflammatory cyto-
kines increased PD-L1 and PD-L2 levels in vitro, these
ligands were not upregulated in MS lesions compared to
controls. In contrast to glial cells, endothelial cells are
sitting at the boundary between the periphery and the
CNS. We can hypothesize that factors, others than pro-
inflammatory cytokines, present in the periphery on the
lumen side, or other CNS cells closely interacting with
the endothelium, may impact on the in vivo PD-L1 and
PD-L2 expression by the CNS endothelium. Finally, we
can speculate that under physiological conditions, the
elevated PD-L2 basal levels contribute to inhibit the
activation and migration of T cells across the BBB, but
given the reduced levels of PD-L2 on MS brain endothe-
lium, this function is impaired. CD8 T cells have been
reported to be localized more frequently in the parench-
yma of MS brain [8,9,45]. Furthermore, we observed an
important PD-L1 upregulation [17] in MS lesions in
perivascular and parenchymal areas, correlating with the
absence of PD-1 on infiltrating CD8 T cells. Therefore,
we speculate that the BBB capacity to control cell entry
into the CNS is impaired in MS patients, leading to the
entry of T cells regardless whether they express PD-1 or
not, but that PD-1-negative CD8 T cells will be favored
for progressing into the inflamed parenchyma which
abundantly expresses PD-L1.
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